JP2023539454A5 - - Google Patents

Info

Publication number
JP2023539454A5
JP2023539454A5 JP2023510443A JP2023510443A JP2023539454A5 JP 2023539454 A5 JP2023539454 A5 JP 2023539454A5 JP 2023510443 A JP2023510443 A JP 2023510443A JP 2023510443 A JP2023510443 A JP 2023510443A JP 2023539454 A5 JP2023539454 A5 JP 2023539454A5
Authority
JP
Japan
Prior art keywords
bacteria
immunostimulatory
section
protein
sting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023510443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539454A (ja
Filing date
Publication date
Priority claimed from US17/320,200 external-priority patent/US20220380720A1/en
Application filed filed Critical
Priority claimed from PCT/US2021/045832 external-priority patent/WO2022036159A2/en
Publication of JP2023539454A publication Critical patent/JP2023539454A/ja
Publication of JP2023539454A5 publication Critical patent/JP2023539454A5/ja
Pending legal-status Critical Current

Links

JP2023510443A 2020-08-12 2021-08-12 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム Pending JP2023539454A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063064869P 2020-08-12 2020-08-12
US63/064,869 2020-08-12
US202163188443P 2021-05-13 2021-05-13
US17/320,200 US20220380720A1 (en) 2019-11-12 2021-05-13 Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
US63/188,443 2021-05-13
US17/320,200 2021-05-13
PCT/US2021/045832 WO2022036159A2 (en) 2020-08-12 2021-08-12 Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms

Publications (2)

Publication Number Publication Date
JP2023539454A JP2023539454A (ja) 2023-09-14
JP2023539454A5 true JP2023539454A5 (https=) 2024-08-15

Family

ID=77951789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510443A Pending JP2023539454A (ja) 2020-08-12 2021-08-12 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム

Country Status (8)

Country Link
EP (1) EP4196139A2 (https=)
JP (1) JP2023539454A (https=)
KR (1) KR20230066000A (https=)
AU (1) AU2021324883A1 (https=)
CA (1) CA3191433A1 (https=)
IL (1) IL300447A (https=)
MX (1) MX2023001782A (https=)
WO (1) WO2022036159A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4241790A1 (en) * 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expression system for the treatment of cancer
EP4241791A1 (en) * 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Combined gene and radio therapy for the treatment of cancer
KR20240034391A (ko) * 2022-09-07 2024-03-14 주식회사 젠라이프 폐암 진단용 전자코 센서 및 이를 이용한 폐암 진단용 전자코 시스템
WO2024096123A1 (ja) * 2022-11-04 2024-05-10 株式会社バイオパレット 遺伝子が改変された微生物およびその生産方法
CN115944722B (zh) * 2023-01-09 2026-02-13 浙江大学 一种抗肿瘤mRNA疫苗及其制备方法和应用
CN116312841B (zh) * 2023-01-10 2026-03-31 中南大学 铁氧化物与金属微观结合形态的预测方法及其应用
CN116212011B (zh) * 2023-03-23 2025-10-10 华中科技大学 一种以细菌为载体的肿瘤个性化疫苗及其制备方法
AU2024301594A1 (en) * 2023-07-26 2026-01-08 Cadmus Animal Health Limited Rna vaccines for use in animal health
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法
CN118436552B (zh) * 2024-04-18 2024-11-26 梅晔生物医药股份有限公司 一种线粒体组合物及其应用、日化品

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3936354A (en) 1974-04-29 1976-02-03 Lapointe Jean Rock Anti-tumour product of bacterial origin
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
EP1021548A1 (en) * 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
JP2001010973A (ja) 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2386806A1 (en) 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2003045153A1 (en) 2001-11-21 2003-06-05 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
WO2003065787A2 (en) 2002-02-06 2003-08-14 Johns Hopkins University School Of Medicine Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US7390646B2 (en) 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
US20070298012A1 (en) 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
WO2006004992A1 (en) 2004-06-29 2006-01-12 Anticancer, Inc. Cancer selective auxotrophs
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN1974759B (zh) 2006-07-26 2010-06-09 吉林大学 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用
FR2920158B1 (fr) * 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
US8241844B2 (en) 2008-10-03 2012-08-14 Ralph Clark, legal representative Methods and compositions for modulating an immune response with immunogenic oligonucleotides
US20120009153A1 (en) 2009-08-13 2012-01-12 Hongnian Guo Compositions for bacterial mediated gene silencing and methods of using the same
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CN103374538B (zh) 2012-04-27 2017-12-01 山东新创生物科技有限公司 包含戈氏梭菌(Clostridiumghonii)的衍生细菌菌株的组合物及其使用方法
US20150126589A1 (en) * 2012-06-08 2015-05-07 Ethris Gmbh Pulmonary Delivery of Messenger RNA
ES2391108B1 (es) 2012-07-26 2013-10-07 Universitat Autonoma De Barcelona Uso de mycobacterium brumae para el tratamiento del cáncer de vejiga
US9539290B2 (en) 2012-12-24 2017-01-10 Anticancer Inc. Individualized bacterial treatment of pancreatic cancer
DK2986311T3 (en) 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
WO2015002969A1 (en) 2013-07-03 2015-01-08 City Of Hope Anticancer combinations
US10987432B2 (en) 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
WO2015153639A1 (en) 2014-03-31 2015-10-08 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
WO2016025582A2 (en) 2014-08-12 2016-02-18 Forbes Neil S Targeting epigenetic regulators using a bacterial delivery system
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
US11273184B2 (en) 2015-08-31 2022-03-15 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
WO2017043815A1 (en) 2015-09-08 2017-03-16 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
BR112019013863A2 (pt) 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
SG11201906552WA (en) 2017-01-25 2019-08-27 Tessa Therapeutics Pte Ltd TGF-ß DECOY RECEPTOR
US20190351040A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Rna cancer vaccines
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN111819185A (zh) 2017-12-15 2020-10-23 旗舰创业创新第六有限责任公司 包含环状多核糖核苷酸的组合物及其用途
JP7340591B2 (ja) * 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) * 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
JP2023501539A (ja) * 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
US20210222178A1 (en) * 2020-01-11 2021-07-22 Sivec Biotechnologies Llc MICROBIAL SYSTEM FOR PRODUCTION AND DELIVERY OF EUKARYOTE-TRANSLATABLE mRNA TO EUKARYA
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Similar Documents

Publication Publication Date Title
JP2023539454A5 (https=)
CA3131017C (en) Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP7346501B2 (ja) ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法
AU2020382614B2 (en) Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
Leitner et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
US20160220652A1 (en) Methods of using recombinant listeria vaccine strains in disease immunotherapy
JP2023534928A (ja) 改変免疫細胞及びその使用
JP2023501539A5 (https=)
US20180153974A1 (en) Combination Therapies With Recombinant Listeria Strains
US20220119824A1 (en) Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CN106413745A (zh) 用于提高效应t细胞与调节性t细胞的比率的方法和组合物
DePeaux et al. Integrating innate and adaptive immunity in oncolytic virus therapy
EP2970427B1 (en) Composition comprised of antigen linked to a tnf superfamily ligand
CA3191433A1 (en) Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CN106794235A (zh) 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
Sartorius et al. Vaccination with filamentous bacteriophages targeting DEC‐205 induces DC maturation and potent anti‐tumor T‐cell responses in the absence of adjuvants
KR20230148226A (ko) 면역조절 분자 및 이의 용도
US20220154136A1 (en) Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
JP2024167172A (ja) 併用療法用dnaワクチンを標的とするネオアンチゲン
JP2024505564A (ja) 自己分極化免疫細胞
Nguyen-Hoai et al. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model
Pasquini et al. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia
Cheng et al. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity
Chen et al. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
Moret-Tatay et al. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors